Related Experiment Video
Updated: Sep 10, 2025
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Antiproliferative Potential of Linagliptin-Rivaroxaban Mixture in Cervical Cancer: Mechanistic Insights into
Buthaina Jasim Yousif1, Doaa Hassan Abd Alwahab1, Haneen A Mohammed2
1College of Education for Pure Sciences, Tikrit University, Iraq.
Background:
Repositioning existing marketed drugs represents a viable strategy for identifying new anticancer agents. This study employed an approach that combined these drugs and examined their molecular mechanisms of action against cancer.
Objective:
This study evaluated the anticancer properties of the linagliptin-rivaroxaban mixture and its molecular anticancer mechanism by screening its ability to target the mutant MAPK-RAS kinase signal proteins.
Methods:
Following 24 and 72 hours of incubation, HeLa and human-derived adipose tissue (NHF) cell lines were utilized to investigate the anticancer and safety properties of a linagliptin-rivaroxaban mixture and cisplatin at concentrations between 0.1 and 1,000 µg/ml. A combination and selectivity index study assessed the potential synergistic effects between mixture ingredients and selective toxicity. Computational molecular docking simulations were employed to investigate the binding affinity of linagliptin and rivaroxaban to various mutant kinase signal proteins within the MAPK-RAS kinase pathway.
Results:
The study results indicated that the combination of linagliptin and rivaroxaban significantly suppressed the growth of cervical cancer cells compared to the inhibitory effects of cisplatin, linagliptin, and rivaroxaban individually. Furthermore, the mixture cytotoxicity on the NHF cell line was significantly lower than that of cisplatin. The interaction between linagliptin and rivaroxaban exhibited synergistic cytotoxicity, as evidenced by the combination index score. The mixture exhibited selective cytotoxicity against cancer cells, suggesting a favorable toxicity index score. The outcomes of the molecular docking pilot study of diverse mutant MAPK-RAS kinase signal proteins with the mixture's ingredients are indicated. Linagliptin and rivaroxaban's best interactions were with mutant P38 MAPK and RAS kinase signal proteins, with docking scores of -7.9 kcal/mol and -8.7 kcal/mol, respectively.
Conclusion:
Regarding the study findings and the established pharmacokinetic and safety profiles of mixture drugs. The linagliptin-rivaroxaban mixture offers an attractive and safer alternative for cervical cancer treatment.
Insights
The linagliptin-rivaroxaban drug combination shows promising anticancer effects against cervical cancer cells, offering a safer alternative to cisplatin. This mixture demonstrates synergistic cytotoxicity and selective targeting of key cancer pathways.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Drug repositioning is a key strategy for discovering novel anticancer agents.
- This study investigates the combined molecular mechanisms of existing drugs against cancer.
Purpose of the Study:
- To evaluate the anticancer properties and molecular mechanisms of a linagliptin-rivaroxaban mixture.
- To assess the mixture's efficacy against mutant MAPK-RAS kinase signal proteins.
Main Methods:
- Utilized HeLa and human-derived adipose (NHF) cell lines for anticancer and safety assessments.
- Performed combination and selectivity index studies, alongside computational molecular docking simulations.
- Investigated binding affinities to mutant kinase signal proteins in the MAPK-RAS pathway.
Main Results:
- Linagliptin-rivaroxaban mixture significantly suppressed cervical cancer cell growth more than individual drugs or cisplatin.
- The mixture exhibited lower cytotoxicity on normal cells compared to cisplatin, indicating selective toxicity.
- Molecular docking revealed strong interactions between linagliptin/rivaroxaban and mutant P38 MAPK/RAS kinase proteins.
Conclusions:
- The linagliptin-rivaroxaban mixture presents a safer and effective alternative for cervical cancer treatment.
- Established pharmacokinetic and safety profiles support its potential clinical application.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
11:13Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:34Inhibition of Cdk Activity
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:23Abnormal Proliferation